This was consistent with the emerging literature on factors associated with CGM use in people with type 1 and type 2 diabetes.12,14 Specifically, insulin dosing may require more frequent blood glucose testing, which may be less burdensome with CGM.12 Some insurers also require that people with type 2 diabetes be on insulin therapy to have CGM covered by insurance, which may be related to the high prevalence of insulin therapy in CGM users. This evidence concerns the gene INS and type 2 diabetes mellitus.